

Trial	Basic Characteristics			Patient Selection			Primary Outcomes				Safety Outcomes				Treatment Effects					
Trial	Year	N	Time Window	Agent	Occlusion	EVT	Imaging Selection	Outcome Measure	Treatment	Control	P-value	sICH Tx	sICH Ctrl	Mortality Tx	Mortality Ctrl	Effect Size	95% CI	ARR	NNT	NNH (sICH)
HOPE	2025	372	4.5-24h	Alteplase 0.9 mg/kg	~63% LVO	No EVT	CTP: Core <70mL	mRS 0-1	40.3%	26.3%	0.004	3.8%	0.5%	10.8%	10.8%	RR 1.52	1.14-2.02	14.0%	7	31
OPTION ★	2026	566	4.5-24h	Tenecteplase 0.25 mg/kg	Non-LVO (~74% MeVO/distal)	No EVT	CTP mismatch	mRS 0-1	43.6%	34.2%	0.02	2.8%	0%	5.0%	3.2%	RR 1.28	1.04-1.57	9.4%	11	35
EXPECTS	2025	234	4.5-24h	Alteplase 0.9 mg/kg	Posterior	No EVT	No extensive hypodensity	mRS 0-2†	89.6%	72.6%	0.01	1.7%	0.9%	5.2%	8.5%	RR 1.16	1.03-1.30	17.0%	6	125
TRACE-III	2024	516	4.5-24h	Tenecteplase 0.25 mg/kg	100% LVO	No EVT	Perfusion CT	mRS 0-1	33.0%	24.2%	0.03	3.0%	0.8%	13.3%	13.1%	RR 1.37	1.04-1.81	8.8%	11	45
TIMELESS	2024	458	4.5-24h	Tenecteplase 0.25 mg/kg	100% LVO	77% EVT	Perfusion CT	Median mRS	3	3	NS	3.2%	2.3%	19.7%	18.2%	OR 1.13	0.82-1.57	—	—	111
CHABLIS-T II	2025	224	4.5-24h	Tenecteplase 0.25 mg/kg	100% LVO	55% EVT	Perfusion CT	Reperfusion‡	33.3%	10.8%	0.001	5.4%	4.4%	10.8%	10.6%	RR 3.0	1.6-5.7	22.5%	4	100
TWIST	2023	578	Wake-up	Tenecteplase 0.25 mg/kg	Unselected (low LVO rate)	No	Non-contrast CT	mRS 0-1	~45%	~38%	NS	2%	1%	10%	8%	OR 1.18	0.88-1.58	—	—	95
EXTEND	2019	225	4.5-9h	Alteplase 0.9 mg/kg	~70% LVO	Rare	CTP mismatch	mRS 0-1	35.4%	29.5%	0.04	6.2%	0.9%	11.5%	8.9%	RR 1.44	1.01-2.06	5.9%	17	19
ECASS4-EXTEND	2019	119	4.5-9h	Alteplase 0.9 mg/kg	Mixed (LVO and non-LVO)	Rare	MRI mismatch	mRS 0-1	NS	NS	NS	1.6%	0%	11.5%	6.8%	—	—	—	—	61
WAKE-UP	2018	503	Unknown	Alteplase 0.9 mg/kg	34% intracranial (mostly distal)	None	DWI-FLAIR mismatch	mRS 0-1	53.3%	41.8%	<0.05	2.0%	0.4%	4.1%	1.2%	OR 1.61	1.09-2.36	11.5%	9	63
EPITHET	2008	101	3-6h	Alteplase 0.9 mg/kg	~60% LVO	None	MRI mismatch	Trend only	—	—	NS	7.1%	0%	13.6%	10.3%	—	—	—	—	14

Evidence Map: Late-Window Thrombolysis by LVO Status		
LVO Status	Trials	Outcome
100% LVO, no EVT	TRACE-III	Clear benefit
100% LVO + bridging EVT	TIMELESS (77% EVT), CHABLIS-T II (55% EVT)	No functional benefit
Mixed LVO (60-70%)	HOPE, EXTEND	Benefit with imaging
Non-LVO (~74% MeVO/distal)	OPTION	Benefit with CTP
Distal occlusions	WAKE-UP (34% intracranial, mostly distal)	Benefit with MRI
Posterior circulation	EXPECTS	Benefit without advanced imaging
Low/unselected LVO	TWIST	No benefit